IDH1/2,   General AML

Eunice Wang | ASCO 2018 | What are the new advances in AML treatment?


 At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Eunice S. Wang from Roswell Park Comprehensive Cancer Center, Buffalo, NY, talks about novel agents including ivosidenib, an oral targeted inhibitor of mutant IDH1, and venetoclax, a BCL-2 inhibitor which have both demonstrated promising results in patients with acute myeloid leukemia (AML).


Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF